The key aspect of FDA's strategy is the request that animal drug sponsors voluntarily work with FDA to revise the approved use conditions for their medically important antimicrobial drug products to remove production uses , and bring the remaining therapeutic uses under veterinary oversight. Once manufacturers voluntarily make these changes, products can no longer be used for production purposes and therapeutic use of these products would require veterinary oversight. (en)
